CORD-19:0329e0f2e3b8ab0eabe2afe0e5214cc88c61080e / 20442-20768 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T114","span":{"begin":0,"end":326},"obj":"Sentence"},{"id":"T99677","span":{"begin":0,"end":326},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The broad spectrum of activity of favipiravir toward RNA viruses has been reviewed, including anti-RNA virus activity in vitro and in vivo in animal models (Delang, Abdelnabi, prophylaxis (PEP) was shown in a mouse model (Smither, et al., 2014) and a therapeutic mouse model of Ebola virus disease (Oestereich, et al., 2014) ."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T114","span":{"begin":0,"end":326},"obj":"Sentence"}],"text":"The broad spectrum of activity of favipiravir toward RNA viruses has been reviewed, including anti-RNA virus activity in vitro and in vivo in animal models (Delang, Abdelnabi, prophylaxis (PEP) was shown in a mouse model (Smither, et al., 2014) and a therapeutic mouse model of Ebola virus disease (Oestereich, et al., 2014) ."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T185","span":{"begin":194,"end":197},"obj":"Disease"},{"id":"T186","span":{"begin":278,"end":297},"obj":"Disease"}],"attributes":[{"id":"A185","pred":"mondo_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/MONDO_0010518"},{"id":"A186","pred":"mondo_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/MONDO_0005737"}],"text":"The broad spectrum of activity of favipiravir toward RNA viruses has been reviewed, including anti-RNA virus activity in vitro and in vivo in animal models (Delang, Abdelnabi, prophylaxis (PEP) was shown in a mouse model (Smither, et al., 2014) and a therapeutic mouse model of Ebola virus disease (Oestereich, et al., 2014) ."}